New advances in pharmacotherapy for early psychosis

Early Intervention in Psychiatry

Volumn 3, Issue SUPPL. 1, 2009, Pages

  Emsley, Robin ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Adherence; Depot formulation; First episode psychosis; Schizophrenia; Second generation antipsychotic

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LONG ACTING DRUG; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

BODY WEIGHT; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; HUMAN; HYPERPROLACTINEMIA; LOW DRUG DOSE; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; REMISSION; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; EARLY DIAGNOSIS; HUMANS; MEDICATION ADHERENCE; RECURRENCE; SCHIZOPHRENIA;

EID: 69449108677     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/j.1751-7893.2009.00124.x     Document Type: Review

References (37)

1. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: A critical review and meta-analysis. Am J Psychiatry 2005; 162: 1785-804.
2. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: A systematic review. Arch Gen Psychiatry 2005; 62: 975-83.
3. Hulshoff Pol HE, Kahn RS. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr Bull 2008; 34: 354-66.
4. Craig TK, Garety P, Power P etal. The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis. Br Med J 2004; 329: 1067.
5. Petersen L, Jeppesen P, Thorup A et al. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. Br Med J 2005; 331: 602.
6. Emsley RA, Oosthuizen P, Joubert A, Roberts MC, Stein DJ. Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. J Clin Psychiatry 1999; 60: 747-51.
7. Lieberman J, Jody D, Geisler S et al. Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993; 50: 369-76.
8. Emsley R, Rabinowitz J, Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry 2006; 163: 743-5.
9. Robinson DG, Woerner MG, Alvir JM et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999; 156: 544-9.
10. Chue P, Emsley R. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs 2007; 21: 441-8.
11. Emsley R, Oosthuizen P, Koen L, Neihaus DJ, Medori R, Rabinowitz J. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: A study with risperidone long-acting injection. Int Clin Psychopharmacol 2008; 23: 325-31.
12. Robinson D, Woerner MG, Alvir JM et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241-7.
13. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002; 106: 286-90.
14. Kane JM. Utilization of long-acting antipsychotic medication in patient care. CNS Spectr 2006; 11: 1-7.
15. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis. Lancet 2009; 373: 31-41.
16. Lehman AF, Lieberman JA, Dixon LB et al. Practice Guidelines for the Treatment of Patients with Schizophrenia, 2nd edn. Arlington, VA: American Psychiatric Association, 2004.
17. National Institute for Health and Clinical Excellence. Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. London, UK: National Institute for Health and Clinical Excellence, 2002.
18. International Early Psychosis Association Writing Group. International clinical practice guidelines for early psychosis. Br J Psychiatry Suppl 2005; 48: S120-4.
19. Zipursky RB, Gu H, Green AI et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005; 187: 537-43.
20. Emsley RA. Risperidone in the treatment of first-episode psychotic patients: A double-blind multicenter study. Risperidone working group. Schizophr Bull 1999; 25: 721-9.
21. Schooler N, Rabinowitz J, Davidson M et al. Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial. Am J Psychiatry 2005; 162: 947-53.
22. Gaebel W, Riesbeck M, Wölwer W et al. Maintenance treatment with risperidone or low dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry 2007; 68: 1763-74.
23. Lieberman JA, Tollefson G, Tohen M et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 2003; 160: 1396-404.
24. Green AI, Lieberman JA, Harner RM et al. Olanzapine and haloperidol in first episode psychosis: Two-year data. Schizophrenia Res 2006; 86: 234-43.
25. Lieberman JA, Phillips M, Gu H et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: A 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003; 28: 995-1003.
26. Robinson DG, Woerner MG, Napolitano B et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry 2006; 163: 2096-102.
27. McEvoy JP, Lieberman JA, Perkins DO et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison. Am J Psychiatry 2007; 164: 1050-60.
28. Kahn RS, Fleischhacker WW, Boter H etal. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet 2008; 371: 1085-97.
29. Andreasen NC, Carpenter WT Jr, Kane JM et al. Remission in schizophrenia: Proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441-9.
30. Adams CE, Fenton MK, Quraishi S et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290-9.
31. Birchwood M, Fiorillo A. The critical period for early intervention. Psychiatr Rehabil Skills 2000; 4: 182-98.
32. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160: 1125-32.
33. Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008; 69: 790-9.
34. Parellada E, Andrezina R, Milanova V et al. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol 2005;19 (Suppl. 5): 5-14.
35. Lasser R, Bossie CA, Zhu Y et al. Long-acting risperidone in young adults with schizophrenia or schizoaffective disorder [abstract NR641]. 157th American Psychiatric Association Annual Meeting; 1-6 May 2004, New York. 2004.
36. Emsley R, Medori R, Koen L et al. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: A preliminary study. J Clin Psychopharmacol 2008; 28: 210-13.
37. Emsley R, Oosthuizen P, Koen L, Niehaus D, Medori R, Rabinowitz J. A cross-study post-hoc comparison of oral vs. injectable antipsychotic treatment in early psychosis. Clin Ther 2008; 30: 2378-86.